What topics does this cannabis study cover?

This study covers research on: Addiction.

Where was this research published?

Published in Neurotoxicology on February 16, 2026.

Safer CBD Alternatives Offer New Hope for Alcohol Disorder Treatment

Synthetic cannabidiol analogues exhibit lower toxicity than cannabidiol and protect against ethanol-induced apoptosis in SH-SY5Y cells.

Neurotoxicology • February 16, 2026 • Moderately Relevant

🤖

AI Summary

Researchers have made a promising breakthrough in developing safer alternatives to cannabidiol (CBD) for treating alcohol use disorder (AUD). The study investigated two synthetic cannabidiol analogues, PQM-242 and PQM-249, which demonstrate significantly improved safety profiles compared to traditional CBD.

In cellular experiments using neuroblastoma cells, the synthetic compounds showed markedly lower toxicity than natural CBD. While cannabidiol had a toxic threshold (LC50) of 44 µM, the new synthetic versions exhibited LC50 values greater than 600 µM. This means the synthetic analogues can be used at much higher concentrations without causing cellular damage. Additionally, all three compounds were found to protect against ethanol-induced cell death and reduce apoptosis, with PQM-242 showing particularly promising results in preventing cellular damage.

The research opens exciting possibilities for developing more effective and safer therapeutic interventions for alcohol use disorder. By creating synthetic versions of cannabidiol that maintain protective properties while reducing potential toxicity, scientists are pushing the boundaries of cannabinoid-based treatments. These findings suggest that modified cannabinoid molecules could provide more targeted and safer therapeutic options for patients struggling with alcohol-related neurological challenges.

📄 Original Abstract

Cannabidiol (CBD) shows therapeutic potential for treating alcohol use disorder (AUD); however, its neurotoxicological profile remains insufficiently characterized, especially when compared with emerging synthetic analogues designed to improve safety. This study compares the neurotoxic and mechanistic profiles of CBD and two synthetic derivatives, PQM-242 and PQM-249, and evaluates their ability to attenuate ethanol-induced cellular injury. Human SH-SY5Y neuroblastoma cells were exposed to increasing concentrations (0.1-1000µM) to generate concentration-response curves, estimate no-observed-adverse-effect levels (NOAELs), and determine cytotoxicity thresholds. Cell viability (MTT), apoptosis (annexin V/propidium iodide), and Bax and Bcl-2 expression (western blot) were assessed after 48h of exposure. CBD showed an LC50 of 44µM, whereas PQM-242 and PQM-249 displayed LC50 values >600µM, indicating markedly lower intrinsic toxicity in the proposed study model. The NOAELs for PQM-242 and PQM-249 were 100µM, compared with 10µM for CBD. For co-exposure studies, 10µM was selected to enable direct comparison under ethanol challenge (250mM). All compounds reduced ethanol-induced loss of viability and apoptosis, and PQM-242 additionally prevented ethanol-mediated Bax upregulation. Overall, PQM-242 and PQM-249 demonstrated enhanced cellular safety and maintained protective activity, supporting their further investigation as candidate molecules for AUD.

Paper Type

📄 Research

Publication

Journal: Neurotoxicology
Published: February 16, 2026
PMID: 41707837
DOI: 10.1016/j.neuro.2026.103411

Authors (12)

Carolina Aparecida Faria Almeida Department of Food and Drugs, School of Pharmaceutical Sciences, Federal University of Alfenas, Rua Gabriel Monteiro da Silva, 700, 37130-001, Alfenas/MG, Brazil.
Gabriela Salles Institute of Environmental, Chemical and Pharmaceutical Sciences, Federal University of São Paulo, Rua São Nicolau, 210, 1° andar, 09913-030, Diadema/SP, Brazil.
Vitor Bruno Department of Clinical and Toxicological Analysis, School of Pharmaceutical Sciences, University of São Paulo, Av. Prof. Lineu Prestes, 580, Bl. 13B, 05508-000, São Paulo/SP, Brazil.
Jessyca Milene Ribeiro Department of Food and Drugs, School of Pharmaceutical Sciences, Federal University of Alfenas, Rua Gabriel Monteiro da Silva, 700, 37130-001, Alfenas/MG, Brazil.
Alessandra Oliveira Silva Department of Food and Drugs, School of Pharmaceutical Sciences, Federal University of Alfenas, Rua Gabriel Monteiro da Silva, 700, 37130-001, Alfenas/MG, Brazil.
+7 more authors